File photo
January 12, 2020 10:08 AM ESTUpdated 10:47 AM
Financing
Pharma

Alex­is Borisy has $200M to back a mar­ket-based plan aimed at cur­ing Amer­i­ca’s drug pric­ing ‘sick­ness’

John Carroll

Editor & Founder

SAN FRAN­CIS­CO — As a high-pro­file fig­ure in the biotech boom that has trans­formed the in­dus­try over the last decade, Alex­is Borisy co-found­ed a slew of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times